Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Jul 2021
Historique:
received: 13 06 2021
revised: 07 07 2021
accepted: 07 07 2021
entrez: 24 7 2021
pubmed: 25 7 2021
medline: 12 8 2021
Statut: epublish

Résumé

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents significant social, economic and political challenges worldwide. SARS-CoV-2 has caused over 3.5 million deaths since late 2019. Mutations in the spike (S) glycoprotein are of particular concern because it harbours the domain which recognises the angiotensin-converting enzyme 2 (ACE2) receptor and is the target for neutralising antibodies. Mutations in the S protein may induce alterations in the surface spike structures, changing the conformational B-cell epitopes and leading to a potential reduction in vaccine efficacy. Here, we summarise how the more important variants of SARS-CoV-2, which include cluster 5, lineages B.1.1.7 (Alpha variant), B.1.351 (Beta), P.1 (B.1.1.28/Gamma), B.1.427/B.1.429 (Epsilon), B.1.526 (Iota) and B.1.617.2 (Delta) confer mutations in their respective spike proteins which enhance viral fitness by improving binding affinity to the ACE2 receptor and lead to an increase in infectivity and transmission. We further discuss how these spike protein mutations provide resistance against immune responses, either acquired naturally or induced by vaccination. This information will be valuable in guiding the development of vaccines and other therapeutics for protection against the ongoing coronavirus disease 2019 (COVID-19) pandemic.

Identifiants

pubmed: 34299045
pii: ijms22147425
doi: 10.3390/ijms22147425
pmc: PMC8306177
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Epitopes, B-Lymphocyte 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Universiti Sains Malaysia
ID : 1001/PPSP/8012382

Références

Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
J Virol. 2004 Dec;78(24):13600-12
pubmed: 15564471
Nat Struct Mol Biol. 2005 Nov;12(11):980-6
pubmed: 16228002
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
Nature. 2021 Apr;592(7852):122-127
pubmed: 33636719
J Virol. 2020 Nov 9;94(23):
pubmed: 32938769
PLoS Biol. 2021 Mar 24;19(3):e3001006
pubmed: 33760807
Protein Sci. 2020 Jul;29(7):1596-1605
pubmed: 32304108
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet Infect Dis. 2021 May;21(5):602
pubmed: 33571446
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Emerg Infect Dis. 2021 Jun;27(6):1673-1676
pubmed: 33784237
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Cell Res. 2017 Jan;27(1):119-129
pubmed: 28008928
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3792-6
pubmed: 15007178
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Science. 2021 Aug 6;373(6555):
pubmed: 34168071
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
Vet Q. 2021 Jan 1;41(1):50-60
pubmed: 33349165
Virus Evol. 2021 Jan 04;7(1):veaa094
pubmed: 33500787
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Nat Commun. 2021 Jan 11;12(1):244
pubmed: 33431842
Protein J. 2021 Jun;40(3):260-295
pubmed: 33629236
Nature. 2021 Aug;596(7871):273-275
pubmed: 34111888
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878
pubmed: 32544429
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6
pubmed: 19321428
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553059
Nature. 2020 Jul;583(7815):282-285
pubmed: 32218527
Emerg Microbes Infect. 2020 Dec;9(1):313-319
pubmed: 32020836
Cell Host Microbe. 2021 May 12;29(5):747-751.e4
pubmed: 33887205
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Nat Commun. 2021 Oct 7;12(1):5868
pubmed: 34620866
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
Nature. 2016 Mar 3;531(7592):114-117
pubmed: 26855426
mBio. 2020 Oct 13;11(5):
pubmed: 33051368
Cell Rep. 2020 Jun 16;31(11):107774
pubmed: 32531208
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162
pubmed: 29073020
Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):839-46
pubmed: 19622868
Environ Health Perspect. 2021 Apr;129(4):47002
pubmed: 33793301
Elife. 2020 Apr 02;9:
pubmed: 32228860
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
mBio. 2021 Aug 31;12(4):e0138621
pubmed: 34311587
mBio. 2014 Feb 25;5(2):e00884-14
pubmed: 24570370
J Virol. 2006 Aug;80(16):7894-901
pubmed: 16873246
J Virol. 2007 Apr;81(7):3151-61
pubmed: 17202208
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Front Cell Infect Microbiol. 2020 Jun 05;10:317
pubmed: 32582574
J Virol. 2008 Aug;82(16):8071-84
pubmed: 18417574
Structure. 2021 Jul 1;29(7):655-663.e4
pubmed: 34111408
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):8094-8103
pubmed: 32198201
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Sci Adv. 2021 Feb 17;7(8):
pubmed: 33597251
J Biol Chem. 2021 Jan-Jun;296:100536
pubmed: 33716040
PLoS Pathog. 2018 Aug 13;14(8):e1007236
pubmed: 30102747
J Clin Med. 2020 May 14;9(5):
pubmed: 32422996
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Lancet Infect Dis. 2021 Aug;21(8):1070
pubmed: 34022142
Emerg Infect Dis. 2021 Apr;27(4):1249-1251
pubmed: 33567246
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9
pubmed: 25288733
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262-12267
pubmed: 27791014
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Antiviral Res. 2018 Jan;149:58-74
pubmed: 29128390
Sci Rep. 2018 Oct 24;8(1):15701
pubmed: 30356097
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
FEBS J. 2013 May;280(9):2002-13
pubmed: 23452147

Auteurs

Mohd Zulkifli Salleh (MZ)

Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Malaysia.

Jeremy P Derrick (JP)

Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.

Zakuan Zainy Deris (ZZ)

Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH